We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
Topical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have important risks, especially with prolonged use at high potency. In the coming months, as a result of regulatory...
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
A patient alert card is being introduced for men taking finasteride to help raise awareness of the risk of psychiatric side effects and sexual dysfunction, including the potential for sexual dysfunction to persist after treatment has stopped. Healthcare professionals are...
How to use a before-and-after study to evaluate your digital health product.
How to use an interrupted time series to evaluate your digital health product.
Information on how the CMA investigated the merger, and how you can find out more.
Advises on how to consider light within the planning system.
How to use a quasi-experimental study to evaluate your digital health product.
Information for health professionals on the epidemiology, transmission and prevention of Chlamydia abortus which can cause stillbirth or abortion in humans.
Find out about the long-term effects some people can have after having COVID-19.
The MHRA will introduce a patient alert card to increase awareness among men taking finasteride about potential psychiatric and sexual side effects
Provides clarity on the need for sustainability appraisal and strategic environmental assessment in relation to plan development.
A statement from the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC).
How to use a multiphase optimisation strategy (MOST) to evaluate your digital health product.
How we assess issues of potential regulatory concern
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).